Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Eur Neurol 1997;38:141–154
(DOI:10.1159/000113368)

Acute Ischemic Stroke Therapy

A Clinical Overview
Zülküf Önal M.a · Fisher M.b

Author affiliations

a Department of Neurology, Akdeniz Üniversitesi Araştirma Hastahanesi, Akdeniz Üniversitesi Tip Fakültesi, Antalya, Turkey; b Department of Neurology and Radiology, University of Massachusetts Medical School, Memorial Health Care, Worcester, Mass., USA

Corresponding Author

Mehmet Zülküf Önal, MD, Department of Neurology, Akdeniz Üniversitesi Araştirma Hastahanesi, Akdeniz Üniversitesi Tip Fakültesi, TR-07058 Antalya (Turkey), Tel. (242) 2274343, Fax (242) 2274490, E-Mail onal@med.akdeniz.edu.tr

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Abstract

Acute ischemic stroke therapy has two basic therapies, dissolving the intravascular occlusion by thrombolytic therapy and protecting the brain from the harmfull cellular, and metabolic consequences of ischemic injury by neuroprotective therapy. It seems most likely that the methods that will be used to treat the acute ischemic stroke patient will be multiple, likely a combination of thrombolytic therapy for early reperfusion and neuroprotective therapy for maintaining vitality. In the last decade, a number of advances in the field of imaging and pharmacology have been made which should provide meaningful improvement for the management of acute ischemic stroke patients in the near future. This update summarizes recent clinical trials and emphasizes the question of risk versus benefit for the acute ischemic stroke therapies being developed.

© 1997 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: January 09, 2008

Number of Print Pages: 14
Number of Figures: 0
Number of Tables: 0

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: http://www.karger.com/ENE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.